HYDERABAD: Laurus Labs Ltd has entered into a strategic partnership agreement with Global Fund for a period of 3.5 years. Through this long term agreement Laurus Labs will have the volume commitments from the Global Fund for the treatment of HIV/AIDS.[the_ad id=”31605″]Under this Partnership agreement Laurus Labs received and executed the order from Global Fund which would cater to the supplies of the high burden diseases countries in Sub Saharan African (SSA) region.
This is the maiden order for Tenofovir/Lamivudine/Dolutegravir 300/300/50mg (TLD) after the Company received a tentative approval from USFDA in the month of February 2019.
Commenting on the development Dr. Satyanarayana Chava, Founder and CEO, Laurus Labs, said, “We’re greatly encouraged by the strategic partnership agreement with Global Fund and also the maiden order for Laurus Labs from Global Fund. We thank Global Fund team for placing its trust for a new entrant like us in ARV – FDF space. For Laurus Labs it is a very significant development which has ventured into the FDFs couple of years ago. This partnership has increased the company’s commitment to contribute to the global mission for treating millions of HIV AIDS patients across the globe.”
Laurus Labs believes that this strategic partnership with Global Fund would increase the access for the HIV/AIDS treatment by meeting the unmet needs, helping to save the lives of millions.
Laurus Labs is a leading research & development driven and fully integrated pharmaceutical company in India.
The Global Fund is a 21st-century partnership organization designed to accelerate the end of AIDS, tuberculosis and malaria as epidemics.